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Abstract
The locus CDKN2A/B (9p21.3), which comprises the tumor suppressors genes CDKN2A
and CDKN2B and the long noncoding RNA (lncRNA) known as ANRIL (or CDKN2B-AS),
was associated with childhood acute lymphoblastic leukemia (ALL) susceptibility in several
genome wide association studies (GWAS). However, the variants associated in the diverse
studies were different. Recently, new and independent SNPs deregulating the locus function
were also identified in association with ALL risk. This diversity in the results may be
explained because different variants in each population could alter CDKN2A/B locus func-
tion through diverse mechanisms. Therefore, the aim of this study was to determine whether
the annotated risk variants in the CDKN2A/B locus affect the susceptibility of B cell precur-
sor ALL (B-ALL) in our Spanish population and explore if other SNPs altering additional reg-
ulatory mechanisms could be also involved. We analyzed the four SNPs proposed by
GWAs and two additional SNPs in miRNA binding sites in 217 pediatric patients with B-ALL
and 330 healthy controls. The SNPs rs2811712, rs3731249, rs3217992 and rs2811709
were associated with B-ALL susceptibility in our Spanish population. ALL subtypes analyses
showed that rs2811712 was associated with B-hyperdiploid ALL. These results provide evi-
dence for the influence of genetic variants at CDKN2A/B locus with the risk of developing B-
ALL.
Introduction
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy [1, 2]. The
genetic basis of ALL susceptibility is broadly supported by its association with certain
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congenital disorders [3] and, more recently, by genome-wide association studies (GWAS).
The two first GWAS independently identified three loci associated with childhood ALL suscep-
tibility: 10q21.2 (ARID5B), 7p12.2 (IKZF1) [4, 5] and 14q11.2 (CEBPE) [5], results widely vali-
dated [3, 6–8]. Some of these loci were associated with specific genetic subtypes of ALL, such as
locus 10q21.2 (ARID5B) and B-hyperdiploid ALL [4, 5]. Subsequent GWAS discovered addi-
tional susceptibility loci at 10p12.2 (BMI1-PIP4K2A) [3], validated in some populations [9], but
not in others [10], and 9p21.3 (CDKN2A/B)[11], a region that comprises the tumor suppressors
genes CDKN2A and CDKN2B and a long noncoding RNA (lncRNA) known as ANRIL.
The region 9p21.3 is particularly noteworthy because independent association signals have
been recently discovered at this locus in association with B cell precursor ALL (B-ALL) suscep-
tibility. The first variant identified in children from the United Kingdom in 2010 was
rs3731217 [11], which is located in intron 1 of CDKN2A. This association was replicated in
several populations such as Germany, Canada [11] and France [12], but not in others like
Poland [13], Hispanic [14] or Thai population [8]. In 2012, Orsi et al. [12] also associated one
variant located in intron 1 of CDKN2A, rs2811709, with B-ALL in French children, a variant
in low linkage disequilibrium (LD) with rs3731217 (r2<0.8). Then, in 2015, three independent
studies using genotyping and imputation-based fine-mapping, pointed to rs3731249 in exon 2
of CDKN2A as the hit associated variant that conferred high risk for B-ALL in European and
Hispanic children [15–17]. Finally, in 2016, Hungate et al., pointed to rs662463 in ANRIL as
an independent locus associated with B-ALL susceptibility in European and African-Ameri-
cans [18].
These variants could alter the locus through diverse mechanisms. The alleles of rs3731217
create two overlapping cis-acting intronic splice enhancer motifs (CCCAGG and CAGTAC)
that may regulate alternative splicing of CDKN2A [18]. The SNP rs3731249 is a missense SNP
in CDKN2Awhich produces an alanine-to-threonine change in amino-acid-sequence, result-
ing in reduced tumor suppressor function of p16INK4A [15]. Interestingly, this SNP is also
located in the 3´UTR region of p14ARF, where it creates a binding site for miR-132-5p and
miR-4642 [19] and could cause the downregulation of the locus. More than other 40 SNPs in
3´UTR region of CDKN2A and CDKN2B that disrupt or create microRNA (miRNA) binding
sites have been described, but studies focused on SNPs in miRNA binding sites are almost
absent. Finally, rs662463 in ANRIL regulates CDKN2B expression by disrupting a transcription
factor binding site for CEBPB [18].
Therefore, although there is an obvious implication of CDKN2A/B locus in B-ALL suscepti-
bility, the variants annotated by the different studies are different and independent. This may
be due to the fact that different variants in each population could alter CDKN2A/B locus func-
tion through diverse mechanisms. Therefore, the aim of this study was to determine the
involvement of these variants at CDKN2A/B locus in the susceptibility of B-ALL in our Spanish
population and explore if SNPs in miRNA binding sites could be also involved in B-ALL risk.
Materials and methods
Ethics statement
The study was approved by the local ethics committee CEIC-E (PI2014039) and was carried
out according to the Declaration of Helsinki. Written informed consent was obtained from all
participants, or from their parents, prior to sample collection.
Study participants
A total of 231 European descent children diagnosed with B-ALL between 2000 and 2011 in the
Pediatric Oncology Units of four Spanish hospitals (University Hospital Cruces, University
CDKN2A/B in pediatric acute lymphoblastic leukemia
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Hospital Donostia, University Hospital La Paz and University Hospital Miguel Servet) and 338
unrelated healthy controls were included in this study (Table 1 and S1 Table). This is the sam-
ple size approximately needed to obtain a statistical power of 80% in a two sided χ2 test given a
significance level of p = 0.05, 1.5 controls per case, a minor allele frequency (MAF) of 10% in
the control group, and an Odd Ratio (OR) of approximately 2 [20].
Data were collected objectively, blinded to genotypes, from the patients’ medical files. The
two most common ALL subtypes, B-lineage hyperdiploid ALL with more than 50 chromo-
somes (B-hyperdiploid ALL) and B-lineage ALL bearing the t(12;21)(p13;q22) translocation
leading to an ETV6-RUNX1 gene fusion, were also analyzed. The other subtypes were not con-
sidered due to the low number of patients in our cohort. Sex and age data were systematically
recorded (Table 1).
Selection of polymorphisms
A total of six SNPs at the locus 9p21.3 were selected (S2 Table). Selection was done based on
the following criteria: “(i) four SNPs previously reported to be highly associated with ALL sus-
ceptibility in the literature. Due to design options, for some of them we selected SNPs in high
LD defined using the International HapMap Project (release #24; http://hapmap.ncbi.nlm.nih.
gov/) (The HapMap Data Coordination Center (DCC), Bethesda, MD) and Haploview soft-
ware v.4.2 (http://www.broad.mit.edu/mpg/haploview/) (Broad Institute, Cambridge, USA)
with an r2 threshold of 0.8. (ii) SNPs in miRNA binding sites of 3´UTR region of CDKN2A
and CDKN2Bwith a MAF>10% identified using bioinformatics tools: Ensembl (http://www.
ensembl.org/) (Welcome Trust Genome Campus, Cambridge, UK), and miRNASNP (http://
bioinfo.life.hust.edu.cn/miRNASNP2/index.php) (College of Life Science and Technology,
HUST). Of 47 SNPs identified in the 3´UTR region that disrupt or create miRNA binding sites
(S3 Table), only two had a MAF>10%.
Table 1. Patient characteristics and genetic alterations in the study population.
Patients Controls
No. of individuals 231 338
Mean age ± SE, y 4.04 ± 3.61 57.8 ± 28.1
Age range, y 1–16 21–101
Sexa
Males, n (%) 128 (55.7) 157 (46.4)
Females, n (%) 102 (44.3) 181 (53.6)
Genetic alterationsb
Hyperdiploid 56 (24.2) -
ETV6-RUNX1 37 (16.0) -
MLL 13 (5.6) -
BCR-ABL 6 (2.6) -
E2A-PBX1 6 (2.6) -
Hypodiploid 2 (0.9) -
Other 1 (0.4) -
No alteration 95 (41.1) -
Not available 21 (9.1) -
SE: standard error, y: years
a There is no data for one patient.
bSix patients have more than one alteration
https://doi.org/10.1371/journal.pone.0177421.t001
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Genotype analyses
Genomic DNA was extracted from remission peripheral blood or bone marrow using the phe-
nol-chloroform method as previously described [21]. DNA was quantified using PicoGreen
(Invitrogen Corp., Carlsbad, CA).
For each sample, 400 ng of DNA were genotyped using the GoldenGate Genotyping Assay
with Veracode technology according to the published Illumina protocol. Data were analyzed
with GenomeStudio software for genotype clustering and calling. Duplicate samples and
CEPH trios (Coriell Cell Repository, Camden, NJ) were genotyped across the plates. For
rs3731249, the genotyping analyses were performed by using PCR followed by restriction anal-
ysis with BstUI enzyme. Duplicates were included in each assay. The PCR products were visu-
alized after electrophoresis on 3% agarose gels. Primer sequences and PCR conditions are
described in detail in S4 Table.
Statistical analysis
To identify any deviation in Hardy-Weinberg equilibrium (HWE) for the healthy controls, a
χ2 test was used. The association between genetic polymorphisms in cases and controls, as
well as ALL subtypes and controls, was also evaluated using the χ2 or Fisher’s exact test. The
effect sizes of the associations were estimated by the odds ratio from univariate logistic regres-
sion. The most significant test among codominant, dominant, recessive, and additive genetic
models was selected. The results were adjusted for multiple comparisons using the false discov-
ery rate (FDR)[22]. In all cases, the significance level was set at 5%.
Results
Genotyping results
A total of 231 patients with B-ALL and 338 unrelated healthy controls were available for geno-
typing with GoldenGate Genotyping Assay. Successful genotyping was achieved for 217
patients with B-ALL and 330 controls (96.1%). Of the SNPs, 5/5 (rs2811712, rs3217992,
rs2811709, rs3731222 and rs1063192) were genotyped satisfactorily (95.6%, 95.3%, 85.4%,
95.3% and 95.6%, respectively). For rs3731249, 180 patients with B-ALL and 235 controls were
available for genotyping with a genotyping rate of 97.6%. All of them were in HWE in the con-
trol cohort.
Genotype association study of B-ALL
Of the 6 SNPs analyzed, we found 4 significantly associated with B-ALL risk (Table 2 and S1
Fig). From them, rs2811712 at CDKN2B displayed the most significant value under the log-
additive genetic model (AA vs AG vs GG). The GG genotype showed a 1.98-fold increased risk
of B-ALL (95% CI: 1.39–2.82; P = 0.0001). The second most significant association signal was
found for rs3731249 at CDKN2A. In this case, the CT/TT genotypes produced a 2.61-fold
increased risk of B-ALL (95% CI: 1.38–4.92; P = 0.002). We also found AA genotype of
rs3217992 associated with a decreased risk of B-ALL (OR: 0.56; 95% CI: 0.36–0.88; P = 0.009).
Finally, rs2811709 AG/AA genotypes were associated with a 1.7-fold increased risk of B-ALL.
All the SNPs remained statistically associated with B-ALL risk after FDR correction. The SNPs
rs3731222 and rs1063192 were not associated with B-ALL susceptibility in our population.
Genotype association study of B-ALL subtypes
When we analyzed the 6 SNPs considering B-hyperdiploid ALL and ETV-RUNX1 ALL sub-
type, we found association between TT genotype of rs3731249 and B-hyperdiploid ALL
CDKN2A/B in pediatric acute lymphoblastic leukemia
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(OR:2.62; 95% CI:1.06–6.48; P = 0.048), AA genotype of rs3217992 with ETV6-RUNX1 ALL
(OR:0.58; 95% CI:0.34–0.96; P = 0.03) and GG genotype of rs2811712 with both B-hyperdi-
ploid ALL (OR:8.69; 95% CI:1.89–40.0; P = 0.007) and ETV6-RUNX1 ALL (OR:2.4; 95%
CI:1.15–5.02; P = 0.024) (Table 3). After FDR correction, the association between rs2811712
and B-hyperdiploid ALL remained statistically significant (p = 0.042).
Discussion
In the current study, we analyzed 6 SNPs at the CDKN2A/B locus in 217 children with B-ALL
and 330 controls in a Spanish cohort. SNPs rs2811712, rs3731249, rs3217992 and rs2811709
were associated with B-ALL susceptibility. In the subtype analysis, rs2811712 was associated
with the risk of developing B-hyperdiploid ALL.
Table 2. Association results of SNPs in CDKN2A/B and B-ALL.
Gene Genotype N (controls) N(cases) OR (CI 95%) P
SNP (N = 330) (N = 217)
ANRIL AA 264 (80.2) 143 (66.5) Additive 0.0001 a
rs2811712 AG 62 (18.8) 64 (29.8) 1.98 (1.39–2.82) (0.0006)
GG 3 (0.9) 8 (3.7)
A 590 (89.7) 350 (81.4) 1.98 (1.39–2.81) 0.0001 a
G 68 (10.3) 80 (18.6) (0.0006)
CDKN2A CC 217 (92.7) 142 (83) Dominant 0.002 a
rs3731249 CT 16 (6.8) 28 (16.4) 2.61 (1.38–4.92) (0.006)
TT 1 (0.4) 1 (0.6)
C 450 (96.2) 312 (91.2) 2.4 (1.31–4.38) 0.004 a
T 18 (3.8) 30 (8.8) (0.012)
CDKN2B, ANRIL GG 95 (28.9) 72 (33.8) Recessive 0.009 a
rs3217992 AG 153 (46.5) 108 (50.7) 0.56 (0.36–0.88) (0.018)
AA 81 (24.6) 33 (15.5)
G 343 (52.1) 252 (59.2) 0.75 (0.58–0.96) 0.023 a
A 315 (47.9) 174 (40.8) (0.034)
CDKN2A GG 203 (79.6) 145 (69.7) Dominant 0.014 a
rs2811709 AG 49 (19.2) 59 (28.4) 1.7 (1.11–2.59) (0.021)
AA 3 (1.2) 4 (1.9)
G 455 (89.2) 349 (83.9) 1.58 (1.08–2.32) 0.017 a
A 55 (10.8) 67 (16.1) (0.034)
CDKN2A AA 246 (74.8) 165 (77.5) Dominant 0.47
rs3731222 AG 78 (23.7) 44 (20.7) 0.86 (0.57–1.29)
GG 5 (1.5) 4 (1.9)
A 570 (86.6) 374 (87.8) 0.9 (0.62–1.29) 0.57
G 88 (13.4) 52 (12.2)
CDKN2B, ANRIL TT 125 (38.1) 86 (39.8) Dominant 0.68
rs1063192 CT 162 (49.4) 98 (45.4) 0.93 (0.65–1.32)
CC 41 (12.5) 32 (14.8)
T 412 (62.8) 270 (62.5) 1.01 (0.78–1.3) 0.91
C 244 (37.2) 162 (37.5)
Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism
a Significant after FDR correction, the p value is displayed in brackets
https://doi.org/10.1371/journal.pone.0177421.t002
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The most significant finding was the association between GG genotype of rs2811712 and
the increased risk of developing B-ALL (p = 10−4). This result is in line with most of the studies
[9, 11, 14, 18]. The SNP rs2811712 is in strong LD with two of the previously reported SNPs,
rs17756311 (r2 = 0.83) and rs662463 (r2 = 1), both associated with B-ALL risk in European
Americans [3, 18] and African Americans [18], respectively. In the subtype analysis, GG geno-
type of rs2811712 was also associated with B-hyperdiploid ALL after FDR correction, result
that is in line with Chokkalingam et al ‘study performed in Hispanics [14]. These associations
could be explained considering that rs2811712 is located in intron 1 of the lncRNA ANRIL.
SNPs in lncRNAs may affect its expression or its structure by interfering with lncRNA folding
or by modulating protein-lncRNA interactions [23]. ANRIL has been shown to regulate
CDKN2A and CDKN2B genes. Specifically, acting in cis, ANRIL binds various Polycomb
Table 3. Association results of SNPs in CDKN2A/B and B-hyperdiploid ALL and ETV6-RUNX1 ALL.
B-hyperdiploid ALL ETV6-RUNX1 ALL
Gene Genotype N (controls) N (cases) OR (CI 95%) P N (cases) OR (CI 95%) P
SNP (N = 330) (N = 54) (N = 37)
ANRIL AA 264 (80.2) 40 (74.1) Recessive 0.007a 22 (62.9) Dominant 0.024
rs2811712 AG 62 (18.8) 10 (18.5) 8.69 (1.89–40.0) (0.048) 12 (34.3) 2.4 (1.15–5.02)
GG 3 (0.9) 4 (7.4) 1 (2.9)
A 590 (91.2) 90 (90.7) 1.73 (0.98–3.05) 0.055 56 (80) 2.16 (1.14–4.1) 0.017
G 68 (8.8) 18 (9.3) 14 (20)
CDKN2A CC 217 (92.7) 39 (83) Dominant 0.048 28 (90.3) Dominant 0.64
rs3731249 CT 16 (6.8) 8 (17) 2.62 (1.06–6.48) 3 (9.7) 1.37 (0.38–4.96)
TT 1 (0.4) 0 0
C 450 (96.2) 86 (91.5) 2.32 (0.98–5.51) 0.55 59 (95.2) 1.27 (0.36–4.44) 0.70
T 18 (3.8) 8 (8.5) 3 (4.8)
CDKN2A GG 203 (79.6) 38 (70.4) Additive 0.06 23 (67.6) Dominant 0.12
rs2811709 AG 49 (19.2) 13 (24.1) 1.72 (0.98–3.01) 11 (32.4) 1.87 (0.86–4.07)
AA 3 (1.2) 3 (5.6) 0
G 455 (89.2) 89 (82.4) 1.76 (0.99–3.11) 0.05 57 (83.8) 1.59 (0.79–3.22) 0.19
A 55 (10.8) 19 (17.6) 11 (16.2)
CDKN2B, ANRIL TT 125 (38.1) 23 (42.6) Dominant 0.53 12 (34.3) Dominant 0.65
rs1063192 CT 162 (49.4) 24 (44.4) 0.83 (0.46–1.49) 17 (48.6) 1.18 (0.57–2.46)
CC 41 (12.5) 7 (13) 6 (17.1)
T 412 (62.8) 70 (64.8) 0.91 (0.59–1.4) 0.68 41 (58.8) 1.19 (0.72–1.97) 0.48
C 244 (37.2) 38 (35.2) 29 (41.4)
CDKN2A AA 246 (74.8) 41 (77.4) Dominant 0.68 27 (77.1) Dominant 0.75
rs3731222 AG 78 (23.7) 12 (22.6) 0.87 (0.44–1.73) 7 (20) 0.88 (0.38–2.01)
GG 5 (1.5) 0 1 (2.9)
A 570 (86.6) 94 (88.7) 0.82 (0.43–1.57) 0.56 61 (87.1) 0.95 (0.45–1.99) 0.90
G 88 (13.4) 12 (11.3) 9 (12.9)
CDKN2B, ANRIL GG 95 (28.9) 17 (31.5) Recessive 0.93 15 (44.1) Aditive 0.030
rs3217992 AG 153 (46.5) 24 (44.4) 0.97 (0.5–1.9) 15 (44.1) 0.58 (0.34–0.96)
AA 81 (24.6) 13 (24.1) 4 (11.8)
G 343 (52.1) 58 (53.7) 0.93 (0.62–1.41) 0.76 45 (66.2) 0.55 (0.32–0.94) 0.028
A 315 (47.9) 50 (46.3) 23 (33.8)
Abbreviations: CI, confidence interval; OR, odds ratio; SNP, single-nucleotide polymorphism
a Significant after FDR correction, the p value is displayed in brackets
https://doi.org/10.1371/journal.pone.0177421.t003
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proteins resulting in histone modification of the CDKN2A/CDKN2B locus, and in turn, silenc-
ing the cluster [24]. In fact, the G allele of rs2811712 was shown to decrease CDKN2B mRNA
levels [25]. Therefore, the G allele of rs2811712 in ANRIL could be involved in the downregula-
tion of the locus, contributing to increased susceptibility to B-ALL.
The second most significant association was found for the CT/TT genotypes of rs3731249,
which produced a 2.6-fold increased risk of B-ALL (P = 0.002). This association was also
described recently by 3 independent studies, all of them pointing out the high impact of this
variant, since it confers in all studies between two and three-fold increased risk of B-ALL sus-
ceptibility in children of European and Hispanic origin [15–17]. Rs3731249 localizes to exon 2
of CDKN2A, being shared by both p16INK4A and p14ARF, the tumor suppressors codified by
CDKN2A. For the p16INK4A, the C-to-T nucleotide substitution resulted in an alanine-to-thre-
onine change (p.A148T). There is evidence that the variant p16INK4A (p.148T) is preferentially
retained in the nucleus, compromising its ability to inhibit CDK4 and CDK6 in the cytoplasm
[15] and favoring proliferation, and therefore contributing to the association with ALL risk. In
p14ARF, rs3731249 is in the 3´UTR region, where the risk allele creates a miRNA binding site
for miR-132-5p and miR-4642 [19]. These miRNAs could downregulate p14ARF expression,
and then, attenuate its function as cyclin inhibitor. Therefore, T allele of rs3731249 in
CDKN2A could be involved in B-ALL through its effect on the function of both p16INK4A and
p14ARF.
The third finding was the association between the AA genotype of rs3217992 and a
decreased B-ALL risk. This SNP is located in a miRNA binding site in CDKN2B in which the
A allele disrupts the binding for miR-138 and miR-205 [26]. The loss of binding of these miR-
NAs could increase the expression of the tumor suppressor CDKN2B, explaining its protective
role. As far as we know, this is the first time that this SNP is associated with B-ALL risk.
Regarding rs2811709, AG/AA genotypes were associated with an increased risk of B-ALL
susceptibility in our population. This SNP was also associated with B-ALL risk in two previous
studies of children of European origin [11, 12]. rs2811709 is a cis-eQTL for CDKN2B, with a
decreased expression of CDKN2B mRNA for the risk allele [25], which could describe the
involvement of rs2811709 in B-ALL.
On the other hand, we found no association between rs3731222 and rs1063192 and B-ALL
susceptibility. One of them, rs3731222, is in high LD with rs3731217 (r2 = 1), the SNP identi-
fied in the work performed by Sherborne et al. [11] and replicated in several studies [9, 12].
However, we and others could not replicate this association [8, 13]. This lack of replication
could be due to differences in the variants that are involved in the disease in the different
populations.
Finally, this study has some limitations that might be addressed, such as the small sample
size compared to other replication studies (13, 14). However, when we calculated the sample
size needed to obtain an 80% of statistical power using the software OpenEpi [20] the esti-
mated size was similar to our cohort. Another limitation could be that the putative function of
miRNA binding site disruption was predicted by in silico tools, but nowadays, the possible
inaccuracy of the prediction algorithms of the databases used has to be assumed.
In conclusion, three of the variants previously proposed by the literature, rs2811712,
rs3731249 and rs2811709, and a new variant, rs3217992, were associated with B-ALL suscep-
tibility in our Spanish cohort. These results confirmed the implication of CDKN2A/B locus
in the development of B-ALL since all these SNPs could act through different mechanisms
that might alter the cluster. The identification of the specific causes that could lead to the
development of B-ALL is clearly a worthwhile goal for prevention or early intervention of
this disease.
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S1 Fig. Diagram of CDKN2A/B locus. In bold, the SNPs significantly associated with B-ALL
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